Loading stock data…
INBX
$89.10-0.03 (-0.03%)
After Hours$89.10+0.00 (+0.00%)· Last close Jun 9
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inhibrx Biosciences, Inc. in the Healthcare sector is trading at $89.10. Wall Street consensus targets $277.50 (2 analysts), implying a +211.4% move over the next 12 months. The stock is currently 43% below its 52-week high of $155.29, remaining 22.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +211.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$89.10
Potential Downside
0%
Whystock Fair Value$89.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Buy
Mean target$277.50+211.4%
Range$230.00 – $325.00
Fundamentals
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
618.90%
Volume
Today's trading volume
247,343
Recent News
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced on May 11 positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study, with the trial evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination […]
Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?
Inhibrx Biosciences recently reported positive interim results from the randomized Phase 2 HexAgon trial, where INBRX-106 plus pembrolizumab doubled the confirmed response rate and generated three complete responses in first-line PD-L1–high head and neck squamous cell carcinoma versus pembrolizumab alone. Beyond tumor shrinkage, the combination triggered very large increases in CD8+ and CD4+ T-cell proliferation and activation, reinforcing INBRX-106’s intended role as a potent T-cell...
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data for INBRX-106 plus KEYTRUDA in head and neck cancer, with plans to move into Phase 3. These updates signal further external partnerships around KEYTRUDA combinations, adding to Merck's oncology pipeline as key patents approach expiry. For investors watching large pharma, Merck's focus on...
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee
This Biotech Stock Surges After Positive Cancer Trial Results. What to Know.
Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.